CEL-SCI Corp (CVM) Announces Proposed Stock Offering streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
FDA acknowledges the great need for improved treatments for head and neck cancer, particularly the locally advanced oral cavity that CEL-SCI is targeting and is open to a close collaboration with CEL-SCI to help demonstrate that Multikine could be such a therapy
Approval is being pursued in other markets including Europe, the United Kingdom, and Canada, where commercialization could possibly begin as early as 2024 if Health Canada clears the submissionÂ
CEL-SCI Corporation: CEL-SCI Concludes Positive Meeting With U S FDA Concerning Multikine s Approval for Head & Neck Cancer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
CEL-SCI REPORTS PHASE 3 TUMOR PD-L1 BIOMARKER DATA DEMONSTRATE MULTIKINE S INCREASED EFFICACY AND POINTS TO POTENTIAL FOR COMBINATION WITH CHECKPOINT INHIBITORS FOR HEAD & NECK CANCER .
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors which most often show longer survival in a proportion of patients with a higher level of tumor cell PD-L1 expression
Combination therapy could boost patient outcomes
CEL-SCI has filed a patent for the use of Multikine in tumor expressing low levels of PD-L1